X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to advance the Company's lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
Lead Product(s): AP‐PA02
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AP‐PA02
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 04, 2024
Details:
AP-SA02 as an adjunct to best available antibiotic therapy and potential treatment for Staphylococcus aureus bacteremia. Initiation of the P2a portion of the study follows Data Review Committee (DRC) review of positive safety and tolerability data from the Phase 1b portion.
Lead Product(s): AP-SA02
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-SA02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
AP-PA02 is a therapeutic phage cocktail that targets the pathogen P. aeruginosa, to treat serious respiratory infections, with an emphasis on patients with cystic fibrosis and non-cystic fibrosis bronchiectasis.
Lead Product(s): AP-PA02
Therapeutic Area: Genetic Disease Product Name: AP-PA02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Armata intends to use the net proceeds from this transaction to continue clinical development of AP-PA02 and AP-SA02. AP-PA02 targets the pathogen P. aeruginosa, to treat serious respiratory infections, with an emphasis on patients with CF and NCFB.
Lead Product(s): AP-PA02
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AP-PA02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva Strategic Opportunities
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 10, 2023
Details:
Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidate AP-PA02 for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
Lead Product(s): AP-PA02
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-PA02
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
AP-SA02 is a novel biologic product candidate comprising natural lytic phages that target the problematic pathogen, Staphylococcus aureus, and offers robust therapeutic attributes, including Potent antimicrobial activity.
Lead Product(s): AP-SA02
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-SA02
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
In pre-clinical studies, AP-SA02 demonstrated potent antimicrobial activity against approximately 95% of S. aureus clinical isolates evaluated, including drug-resistant strains, and, we believe, due to its potency and biofilm activity.
Lead Product(s): AP-SA02
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-SA02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Armata intends to use the net proceeds from this transaction to advance its clinical pipeline and strengthen its bacteriophage platform. The clinical pipeline is led by AP-PA02, currently under evaluation.
Lead Product(s): AP-PA02
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-PA02
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innoviva Strategic Opportunities LLC
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 11, 2022
Details:
Company Announces FDA clearance of IND to initiate Phase 1b/2a clinical trial of AP-SA02 in Staphylococcus aureus bacteremia as an adjunct to best available antibiotic therapy.
Lead Product(s): AP-SA02
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-SA02
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
Details:
The SWARM-P.a. study will the first FDA cleared Phase 1b/2a, controlled clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects with cystic fibrosis and chronic pulmonary Pseudomonas aeruginosa infection.
Lead Product(s): AP-PA02
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-PA02
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
